|
|
|
|
|
Bupropion: profile and news
Bayer's share price falls on 4Q results 06 Mar 2006 Wenning: 2005 a very successful year for Bayer 06 Mar 2006 Fremont can counter terrorism 06 Mar 2006 Renee Cipro and Jessi Lieb Named to Tewaaraton Trophy Preseason ... Feb 27, 2006 Jon Barron's Super ViraGon beats infection that even Cipro couldn' ... Feb 6, 2006 MENINGITIS EXPOSED NEED CIPRO Feb 24, 2006 Second opinion will clear up confusion Mar 3, 2006 Local non-profit org on the cards to fight Microsoft patent Mar 2, 2006 District athletes stand out on campus Feb 28, 2006 Antibiotic gatifloxacin (Tequin) poses health risks Mar 1, 2006 Couple & son also got hides from lone victim Feb 24, 2006 Student dies of meningitis in Cabra Feb 23, 2006 Antibiotic Given to Loyola Students Feb 23, 2006 No. 11 Women's Lacrosse Opens 2006 Season at No. 15 Vanderbilt Feb 24, 2006 Meningitis scare at Avon school Feb 16, 2006 Youth Hockey Roundup Feb 8, 2006 Good thrax news as victim battles Feb 27, 2006 INDIA: LAST OF A SERIES Feb 11, 2006 NYC Man's Anthrax Still Not a Threat, Still Mysterious Feb 24, 2006 Three Nittany Lions Earn All-American Lacrosse Conference ... Feb 20, 2006 Women's Lacrosse Hosts Penn Saturday in home opener Feb 28, 2006 Last season's success fuels lacrosse squad Feb 22, 2006 BAD BUGS, NO DRUGS ; Our Dwindling Pill Arsenal Can't Fight New ... Mar 2, 2006 Hoya Notebook Feb 28, 2006 Reps seek direct talks with drug companies Feb 27, 2006 Tequin Linked to High Risk of Dangerous Glucose Changes Mar 1, 2006 The Rich Are Different Feb 5, 2006 Hoyas Travel to Pennsylvania for Quad-Scrimmage Feb 17, 2006 Call for calm as anthrax is back Feb 23, 2006 In 'serious trouble,' says Mike Feb 25, 2006 (BW) Alcon's Fourth Quarter Sales Rise 10.7 Percent Feb 8, 2006 Novelist is undone by Sept. 11 story Feb 19, 2006 Drum Maker in Brooklyn Has No Fear of Anthrax Feb 23, 2006 Poppin' Jay Feb 19, 2006 Disaster changes the way upper-crust New Yorkers see their world Feb 19, 2006 Authorities Continue Search For Anthrax Origin Feb 23, 2006 Women's Lacrosse Begins 2006 Season at Mt. St. Mary's Feb 24, 2006 Eager Penn State burning to get on the playing field Feb 24, 2006 3 Cats on Tewaaraton Watch List Feb 23, 2006 NEWSWEEK COVER: Cheney's Secret World Behind The Shooting Furor Feb 19, 2006 Modern Marco Polos Feb 5, 2006 Watch Out for Georgetown Feb 14, 2006 DC-Based Public Affairs Shop Wins 2nd National PR Award for 2005 ... Feb 13, 2006 Looking up at Mother Mountain Feb 9, 2006 Mom's favorite candidate Feb 3, 2006 Other information Indication For the treatment of depression and as aid to Smoking cessation. Pharmacology Bupropion, an antidepressant of the aminoketone class and a non-nicotine aid to smoking cessation, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behavior tasks, and, at high doses, induction of mild stereotyped behavior. Mechanism Of Action Bupropion selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotonin; actions on dopaminergic systems are more significant than imipramine or amitriptyline whereas the blockade of norepinephrine and serotonin reuptake at the neuronal membrane is weaker for bupropion than for tricyclic antidepressants. The increase in norepinephrine may attenuate nicotine withdrawal symptoms and the increase in dopamine at neuronal sites may reduce nicotine cravings and the urge to smoke. Bupropion exhibits moderate anticholinergic effects. Drug Category Antidepressants; Antidepressants; ATC:N07BA02 Brand Names/Synonyms Bupropion; Bupropion Hcl; Wellbatrin; Wellbutrin; Wellbutrin Sr; Wellbutrin Xl; Zyban Dosage Forms immediate and sustained release tablets Absorption for sustained release, peak plasma conc. are achieved within 3 hours. Interactions -->Interactions for Bupropion: Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs. Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity. In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide). The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes. The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers. Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion. While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin). Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans. In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism. Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs. Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied. Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication. If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index. MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine . Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine. Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases. Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution. Low initial dosing and small gradual dose increases should be employed. Nicotine Transdermal System: . Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN. The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see CONTRAINDICATIONS). |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |